目的 探討當(dāng)歸龍薈片聯(lián)合前列地爾治療肝火上炎型突發(fā)性耳聾的臨床療效。方法 選取2021年6月—2023年6月秦皇島市中醫(yī)醫(yī)院收治的突發(fā)性耳聾患者120例，采用隨機(jī)數(shù)字法將患者分為對(duì)照組（60例）和治療組（60例）。對(duì)照組靜脈滴注注射用前列地爾，2 mL加入生理鹽水100 mL，1次/d。在對(duì)照組的基礎(chǔ)上，治療組患者口服當(dāng)歸龍薈片，4片/次，2次/d。兩組患者用藥15 d。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀緩解時(shí)間，耳鳴致殘量表評(píng)分（THI）和歐洲五維生活質(zhì)量量表評(píng)分（EQ-5D-3L）評(píng)分，及同型半胱氨酸（Hcy）、降鈣素基因相關(guān)肽（CGRP）、D-二聚體（D-D）和可溶性血管細(xì)胞黏附分子-1（sVCAM-1）水平。結(jié)果 治療后，治療組總有效率為96.67%，明顯高于對(duì)照組總有效率（85.00%，P＜0.05）。治療后，治療組癥狀緩解時(shí)間比對(duì)照組明顯縮短（P＜0.05）。治療后，兩組患者THI評(píng)分、EQ-5D-3L評(píng)分比治療前明顯降低（P＜0.05），且治療后治療組THI評(píng)分、EQ-5D-3L評(píng)分均明顯低于對(duì)照組（P＜0.05）。治療后，兩組患者Hcy、DD和sVCAM-1水平比治療前明顯降低，而CGRP水平明顯升高（P＜0.05），且治療后治療組Hcy、DD、sVCAM-1和CGRP水平明顯好于對(duì)照組（P＜0.05）。結(jié)論 當(dāng)歸龍薈片與前列地爾協(xié)同治療，可顯著好轉(zhuǎn)突發(fā)性耳聾患者的癥狀及體征，機(jī)體炎癥反應(yīng)明顯減弱。

Objective To explore the clinical effect of Danggui Longhui Tablets combined with alprostadil in treatment of sudden deafness caused by liver-fire inflammation. Methods Patients (120 cases) with sudden deafness caused by liver-fire inflammation in Qinhuangdao Traditional Chinese Medicine Hospital from June 2021 to June 2023 were divided into control (60 cases) and treatment (60 cases) group by random number method. Patients in the control group were iv administered with Alprostadil for injection, 2 mL added into normal saline 100 mL, once daily. Patients in the treatment group were po administered with Danggui Longhui Tablets, 4 tablets /time, twice daily. Patients in two groups were treated for 15 d. After treatment, the clinical evaluations were evaluated, the symptom relief time, the scores of THI and EQ-5D-3L, and the levels of Hcy, D-D, sVCAM-1 and CGRP in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was 96.67%, which was significantly higher than that in the control group (85.00%, P < 0.05). After treatment, the symptom relief time in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the THI score and EQ-5D-3L score in both groups were significantly lower than those before treatment (P < 0.05), and the scores in the treatment group were significantly lower than that in the control group (P < 0.05). After treatment, the levels of Hcy, D-D and sVCAM-1 in two groups were significantly lower than those before treatment, while the levels of CGRP were significantly increased (P < 0.05). After treatment, the levels of Hcy, D-D, sVCAM-1, and CGRP in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion The coordinated treatment of alprostadil and Danggui Longhui Tablets can significantly improve the symptoms and signs of patients with sudden deafness, and the inflammatory response is significantly weakened.

R987

秦皇島市科學(xué)技術(shù)研究與發(fā)展計(jì)劃項(xiàng)目(202005A046)